Quality of life of children with mucopolysaccharidoses on the background of enzyme replacement therapy

Introduction. Mucopolysaccharidoses (MPSs) represent a group of rare lysosomal storage diseases, associated with the decline in  life expectancy and impairing  it’s quality. Despite prolonged evaluation of the effectiveness of pathogenic therapy, patient-reported outcomes are poorly defined. The aim of the study. To describe the impact of enzyme-replacement therapy (ERT) on the quality of life in MPS children, using parent-completed validated questionnaires.

Materials and methods. Parents of forty five MPSs children (27 — with neuronopathic disease, 18- with non-neuronopathic disease, 31 among them were treated with ERT) completed parent proxy-report of Pediatric Quality of Life Inventory™ (PedsQL™) 4.0 Generic Core Scales. Parents of seventeen children (10 — with neuronopathic disease), treated with ERT, completed PedsQL™ 4.0 Generic Core Scales twice, parents of 7 children with non-neuronopathic disease, treated with ERT, completed Childhood Health Assessment Questionnare (CHAQ) and visual analogue scale (VAS) of pain and overall health status, parents of 10 children with neuronopathic disease, treated with ERT, completed VAS of pain and overall health status twice. Cross-sectional and dynamic analyses have been undertaken. 

Results. Stabilization and lack of significant improvement of functional disability, quality of life and VAS scores of pain and overall health status have been demonstrated. In 57% of patients with non-neuronopathic disease, treated with ERT, mean score of «School Functioning» decreased, in 80% of patients with neuronopathic disease, treated with ERT, mean score of «Physical Functioning» decreased. In 50% of children with neuronopathic disease and in 57% of children with non-neuronopathic disease, mean score of «Emotional Functioning» improved. 

Conclusion. MPS children, treated with ERT, require additional psychological and educational help, as well as regular motor rehabilitation. 

Contribution: 
Osipova L.A. — concept, data collection, data processing and analysis, text writing, text editing;
Kuzenkova L.M. — concept, text editing; 
Chernikov V.V. — concept, data processing;
Podkletnova T.V. — text editing.
All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare participation in educational activities with the support of Takeda Pharmaceutical Company.

Received: April 04, 2022
Accepted:  May 12, 2022
Published: June 30, 2022

1. Neufeld E., Muenzer J. The mucopolysaccharidosis. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D., eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 2001: 3421–52.

2. Giugliani R., Federhen A., da Silva A.A., Bittar C., Souza C.M., Netto C. Emerging treatment options for the mucopolysaccharidoses. Res. Rep. Endocr. Disord. 2012; 2: 53–64. https://doi.org/10.2147/RRED.S24769

3. Hendriksz C.J., Berger K.I., Lampe C., Kircher S.G., Orchard P.J., Southall R., et al. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet. J. Rare Dis. 2016; 11(1): 119. https://doi.org/10.1186/s13023-016-0503-2

4. Raluy-Callado M., Chen W.H., Whiteman D.A., Fang J., Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet. J. Rare Dis. 2013; 8: 101. https://doi.org/10.1186/1750-1172-8-101

5. Barranger J.A., Cabrera-Salazar M.A. Lysosomal Storage Disorders. Berlin: Springer; 2007.

6. Bjoraker K.J., Delaney K., Peters C., Krivit W., Shapiro E.G. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J. Dev. Behav. Pediatr. 2006; 27(4): 290–6. https://doi.org/10.1097/00004703-200608000-00002

7. Clarke L.A. Mucopolysaccharidosis Type I. In: Adam M.P., Ardinger H.H., Pagon R.A., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; c1993-2019. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1162/

8. Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalás O., Pinto L.L., et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet. Mol. Biol. 2010; 33(4): 589–604. https://doi.org/10.1590/s1415-47572010005000093

9. Drugs@FDA: FDA-Approved Drugs. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/

10. European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines

11. Brands M.M., Güngör D., van den Hout J.M., Karstens F.P., Oussoren E., Plug I., et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J. Inherit. Metab. Dis. 2015; 38(2): 323–31. https://doi.org/10.1007/s10545-014-9737-0

12. Guffon N., Heron B., Chabrol B., Feillet F., Montauban V., Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet. J. Rare Dis. 2015; 10: 43. https://doi.org/10.1186/s13023-015-0259-0

13. Matos M.A., Ferri-de-Barros F., Guarniero R. Quality of life evaluation in patients with mucopolysaccharidosis using PedsQL. J. Child Health Care. 2019; 23(2): 278–85. https://doi.org/10.1177/1367493518787319

14. Needham M., Packman W., Quinn N., Rappoport M., Aoki C., Bostrom A., et al. Health-related quality of life in patients with MPS II. J. Genet. Couns. 2015; 24(4): 635–44. https://doi.org/10.1007/s10897-014-9791-7

15. Politei J.M., Gordillo-González G., Guelbert N.B., de Souza C.F.M., Lourenço C.M., Solano M.L., et al. Recommendations for evaluation and management of pain in patients with mucopolysaccharidosis in Latin America. J. Pain Symptom. Manage. 2018; 56(1): 146–52. https://doi.org/10.1016/j.jpainsymman.2018.03.023

16. Shapiro E.G., Rudser K., Ahmed A., Steiner R.D., Delaney K.A., Yund B., et al. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol. Genet. Metab. Rep. 2016; 7: 32–9. https://doi.org/10.1016/j.ymgmr.2016.03.005

17. Giugliani R., Harmatz P., Lin S.P., Scarpa M. Assessing the impact of the five senses on quality of life in mucopolysaccharidoses. Orphanet. J. Rare Dis. 2020; 15(1): 97. https://doi.org/10.1186/s13023-020-01368-x

18. Varni J.W., Seid M., Rode C.A. The PedsQL: measurement model for the pediatric quality of life inventory. Med. Care. 1999; 37(2): 126–39. https://doi.org/10.1097/00005650-199902000-00003

19. National Institute of Environmental Health Sciences (NIEHS). Childhood Health Assessment Questionnaire (instruction). Available at: https://www.niehs.nih.gov/research/resources/assets/docs/chaq_instructions_508.pdf

20. Rebrova O.Yu. Statistical Analysis of Medical Data. Application of the STATISTICA [Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA]. Moscow: Mediasfera; 2002. (in Russian)

21. Dempster H., Porepa M., Young N., Feldman B.M. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum. 2001; 44(8): 1768–74. https://doi.org/10.1002/1529-0131(200108)44:8<1768::AID-ART312>3.0.CO;2-Q

22. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009; 123(1): 229–40. https://doi.org/10.1542/peds.2007-3847

23. Muenzer J., Beck M., Eng C.M., Giugliani R., Harmatz P., Martin R., et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet. Med. 2011; 13(2): 95–101. https://doi.org/10.1097/gim.0b013e3181fea459

24. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005; 115(6): e681–9. https://doi.org/10.1542/peds.2004-1023

25. Lin H.Y., Chen M.R., Chuang C.K., Chen C.P., Lin D.S., Chien Y.H., et al. Enzyme replacement therapy for mucopolysaccharidosis VI – experience in Taiwan. J. Inherit. Metab. Dis. 2010; 33(Suppl. 3): S421–7. https://doi.org/10.1007/s10545-010-9212-5

26. Lin H.Y., Chuang C.K., Wang C.H., Chien Y.H., Wang Y.M., Tsai F.J., et al. Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series. Mol. Genet. Metab. Rep. 2016; 7: 63–9. https://doi.org/10.1016/j.ymgmr.2016.04.003

27. Giugliani R., Lampe C., Guffon N., Ketteridge D., Leão-Teles E., Wraith J.E., et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) – 10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am. J. Med. Genet. A. 2014; 164A(8): 1953–64. https://doi.org/10.1002/ajmg.a.36584

28. Tylki-Szymanska A., Marucha J., Jurecka A., Syczewska M., Czartoryska B. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J. Inherit. Metab. Dis. 2010; 33(2): 151–7. https://doi.org/10.1007/s10545-010-9059-9

29. Parini R., Rigoldi M., Tedesco L., Boffi L., Brambilla A., Bertoletti S., et al. Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients. Mol. Genet. Metab. Rep. 2015; 3: 65–74. https://doi.org/10.1016/j.ymgmr.2015.03.011

30. Brands M.M., Oussoren E., Ruijter G.J., Vollebregt A.A., van den Hout H.M., Joosten K.F., et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol. Genet. Metab. 2013; 109(1): 70–6. https://doi.org/10.1016/j.ymgme.2013.02.013